Zenas BioPharma, Inc.
Financials
Valuation Metrics
Zenas BioPharma, Inc.'s Market Cap is $1.85B. At end of 2025 it was $1.69B. Ranked #2033 of 3,116 in US market (top 65%), #774 of 1,472 on NASDAQ (top 53%), #144 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.85B | US#2,033/3,116 Sec#144/265 |
| Revenue | $1M | US#2,846/3,116 Sec#188/265 |
| Net Income | $-484M | US—/3,116 Sec—/265 |
| Total Assets | $702M | US#2,619/3,116 Sec#131/265 |
| Net Assets | $247M | US#2,586/3,116 Sec#169/265 |
| Employees | 167 | US#2,511/3,116 Sec#135/265 |
| Value | ||
| P/B | 7.49x | US#2,485/3,116 Sec#177/265 |
| P/S | 185.04x | US#2,952/3,116 Sec#184/265 |
| FCF Yield | -12.21% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -196.03% | US#2,834/3,116 Sec#218/265 |
| ROA | -69.03% | US#3,025/3,116 Sec#239/265 |
| Op. Margin | -47557.30% | US#2,856/3,116 Sec#190/265 |
| Revenue Growth | -93.33% | US#2,720/3,116 Sec#177/265 |
| Financial Health | ||
| Debt Ratio | 183.97% | US#1,701/3,116 Sec#193/265 |
| Total Debt | $390M | US#2,001/3,116 Sec#73/265 |
| FCF | $-226M | US#2,802/3,116 Sec#219/265 |
| Cash | $197M | US#1,741/3,116 Sec#110/265 |
| Current Ratio | 9.93x | US#249/3,116 Sec#78/265 |
| Performance | ||
| 1Y Return | -4.99% | US#1,734/3,116 Sec#146/265 |
| 1M Return | 5.27% | US#963/3,116 Sec#66/265 |
| From 52W High | -36.35% | US#2,229/3,116 Sec#156/265 |
| 1Y MDD | -64.79% | US#2,843/3,116 Sec#222/265 |
| Trading | ||
| Volume | 346,742 shares | US#2,320/3,116 Sec#222/265 |
| Trading Value | $10M | US#2,275/3,116 Sec#181/265 |
| Per Share | ||
| EPS | $-7.43 | US—/3,116 Sec—/265 |
| BPS | $3.79 | US#2,379/3,116 Sec#142/265 |
Company Info
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.